Pathstone Family Office’s Gilead Sciences GILD Stock Holding History

Pathstone Family Office’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-600	Closed	-$387K	–	204
2016 Q1	$387K	Buy	+600	New	+$54.1K	0.78%	18
2015 Q1	–	Sell	-594	Closed	-$965K	–	124
2014 Q4	$965K	Buy	+594	New	+$61.4K	3.28%	5
2014 Q1	–	Sell	-58,700	Closed	-$152K	–	211
2013 Q4	$152K	Buy	+58,700	New	+$4.09M	0.33%	14

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Pathstone Family Office's GILD Position: Q3 2023 in Review

Pathstone Family Office increased its Gilead Sciences (GILD) stake by 254% in Q3 2023, buying an estimated $2.88M and bringing the position to 52,159 shares worth $3.94M. The position accounts for 0.03% of the portfolio, ranked #321.

Pathstone Family Office first reported a position in GILD in Q2 2013 and has held it in 37 quarters since. The position peaked at $6.33M in Q3 2014. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

Pathstone Family Office held 52,159 shares of Gilead Sciences worth $3.94M as of Q3 2023.
Pathstone Family Office bought 37,417 Gilead Sciences shares in Q3 2023, an estimated $2.88M.
Gilead Sciences made up 0.03% of Pathstone Family Office's portfolio in Q3 2023, its #321 holding.
Pathstone Family Office first reported a position in Gilead Sciences in Q2 2013 and has held it in 37 quarters since.
Pathstone Family Office's Gilead Sciences position peaked at $6.33M in Q3 2014.
1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.